Clinical Trial Update: Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating an augmented stem cell mobilization strategy using Plerixafor (Mozobil) in patients at risk for poor mobilization, in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Mozobil (plerixafor)

Snippet

Sponsor: CancerCare Manitoba | Conditions: Multiple Myeloma, Lymphoma | Phase 2 | Status: COMPLETED